期刊
PEDIATRIC BLOOD & CANCER
卷 68, 期 1, 页码 -出版社
WILEY
DOI: 10.1002/pbc.28739
关键词
ALL; ALL relapse; immunotherapy; pediatric hematology; oncology
资金
- Medical College of Wisconsin's Division of Pediatric Hematology/Oncology/Bone Marrow Transplant
CAR T-cell therapy has shown successful application in patients with KMT2Ar infant ALL, offering potential efficacy for patients with extramedullary disease.
Chimeric antigen receptor (CAR) T-cells, engineered autologous T-cells that target antigens found in leukemia, have shown durable remissions in relapsed acute lymphoblastic leukemia (ALL). Infant ALL withKMT2Arearrangements (KMT2Ar) is a rare, aggressive form of leukemia associated with extramedullary disease both at diagnosis and at relapse, and overall outcomes for these patients are dismal. Here we report the successful use of tisagenlecleucel, a CAR T-cell product approved for relapsed/refractory ALL, in a patient withKMT2Ar infant ALL who was treated for combined marrow and extramedullary (renal) relapse.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据